TG THERAPEUTICS, INC. Proceeds from Maturities, Prepayments and Calls of Held-to-maturity Securities
TG THERAPEUTICS, INC. (TGTX) reported Proceeds from Maturities, Prepayments and Calls of Held-to-maturity Securities of $29.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities · last filed 2026-08-05
- TG THERAPEUTICS, INC. proceeds from maturities, prepayments and calls of held-to-maturity securities for the quarter ending 2026-06-30 was $17.75M, a 64.03% decline year-over-year.
- TG THERAPEUTICS, INC. proceeds from maturities, prepayments and calls of held-to-maturity securities for the quarter ending 2026-03-31 was $11.25M, a 86.01% decline year-over-year.
- TG THERAPEUTICS, INC. proceeds from maturities, prepayments and calls of held-to-maturity securities for the quarter ending 2025-12-31 was $30.00M, a 59.29% decline year-over-year.
- TG THERAPEUTICS, INC. proceeds from maturities, prepayments and calls of held-to-maturity securities for the quarter ending 2025-09-30 was $77.75M, a 15.76% decline year-over-year.
- TG THERAPEUTICS, INC. proceeds from maturities, prepayments and calls of held-to-maturity securities for fiscal 2025 was $237.50M, a 23.61% decline from fiscal 2024.
- TG THERAPEUTICS, INC. proceeds from maturities, prepayments and calls of held-to-maturity securities for fiscal 2024 was $310.90M, a 223.08% increase from fiscal 2023.
- TG THERAPEUTICS, INC. proceeds from maturities, prepayments and calls of held-to-maturity securities for fiscal 2023 was $96.23M.
| Period end | Proceeds from Maturities, Prepayments and Calls of Held-to-maturity Securities 3 month | Proceeds from Maturities, Prepayments and Calls of Held-to-maturity Securities 6 month | Proceeds from Maturities, Prepayments and Calls of Held-to-maturity Securities 9 month | Proceeds from Maturities, Prepayments and Calls of Held-to-maturity Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $17.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $29.00M 10-Q · filed 2026-08-05 | $59.00M derived: sum of 3 quarters · filed 2026-08-05 | $136.75M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $11.25M 10-Q · filed 2026-05-06 | $41.25M derived: sum of 2 quarters · filed 2026-05-06 | $119.00M derived: sum of 3 quarters · filed 2026-05-06 | $168.35M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $30.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $107.75M derived: sum of 2 quarters · filed 2026-02-27 | $157.10M derived: sum of 3 quarters · filed 2026-08-05 | $237.50M 10-K · filed 2026-02-27 |
| 2025-09-30 | $77.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $127.10M derived: sum of 2 quarters · filed 2026-08-05 | $207.50M 10-Q · filed 2025-11-05 | $281.20M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $49.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $129.75M 10-Q · filed 2026-08-05 | $203.45M derived: sum of 3 quarters · filed 2026-08-05 | $295.75M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $80.40M 10-Q · filed 2026-05-06 | $154.10M derived: sum of 2 quarters · filed 2026-05-06 | $246.40M derived: sum of 3 quarters · filed 2026-05-06 | |
| 2024-12-31 | $73.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $166.00M derived: sum of 2 quarters · filed 2026-02-27 | $310.90M 10-K · filed 2026-02-27 | |
| 2024-09-30 | $92.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $237.20M 10-Q · filed 2025-11-05 | ||
| 2024-06-30 | $144.90M 10-Q · filed 2025-08-08 | |||
| 2023-12-31 | $96.23M 10-K · filed 2026-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |